Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment

Background/Aims: Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to study the treatment and side effects of GLE/PIB in these patients infected with n...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and molecular hepatology 2020, 26(4), , pp.554-561
Hauptverfasser: Yap, Desmond Y. H., Liu, Kevin S. H., Hsu, Yu-Chun, Wong, Grace L. H., Tsai, Ming-Chang, Chen, Chien-Hung, Hsu, Ching-Sheng, Hui, Yee Tak, Li, Michael K. K., Liu, Chen-Hua, Kan, Yee-Man, Yu, Ming-Lung, Yuen, Man-Fung
Format: Artikel
Sprache:eng
Schlagworte:
glecaprevir and pibrentasvir
Hepatitis C
Kidney diseases
Liver cancer
Original
Peritoneal dialysis
renal insufficiency
내과학
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background/Aims: Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to study the treatment and side effects of GLE/PIB in these patients infected with non-1 genotype (GT) HCV.Methods: We prospectively recruited patients with Child’s A cirrhosis and eGFR
ISSN:2287-2728
2287-285X
DOI:10.3350/cmh.2020.0058